The Dales Report – MINDCURE CEO Kelsey Ramsden on Exciting Ibogaine Synthesis Patent News

Shadd Dales interviewed MINDCURE CEO Kelsey Ramsden about some exciting news: the Maxim Group started coverage on MINDCURE. This allows investors to better understand MINDCURE’s strategy. Furthermore, MINDCURE announced two provisional patents for artificial ibogaine synthesis processes. This route offers a consistent supply for research purposes, a higher chance of FDA approval, and first-mover advantage.

Access the interview here.